IL17A and breast carcinoma: Interleukin-17 (IL-17) family cytokines are potent drivers of inflammatory responses [21]; however, recent studies also revealed IL-17 as an immune marker in patients with bladder cancer [23], breast cancer [24], non-small cell lung cancer [25], renal cell carcinoma [26], and colorectal cancer [27].